Lenalidomide augments actin remodelling and lowers NK cell activation thresholds.
Lagrue K et al. Blood. 2015 May 22. pii: blood-2015-01-625004. [Epub ahead of print].
CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in Multiple Myeloma.
Yousef S et al. Hum Vaccin Immunother. 2015 May 22:0. [Epub ahead of print].
MicroC3: an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.
Pak C et al. Integr Biol (Camb). 2015 May 22. [Epub ahead of print].
Ginsenoside Rg3 induces apoptosis in human multiple myeloma cells via the activation of Bcl-2-associated X protein.
Luo Y et al. Mol Med Rep. 2015 May 19. doi: 10.3892/mmr.2015.3802. [Epub ahead of print].
Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies.
Kitatani K et al. Mol Cells. 2015 May 22. doi: 10.14348/molcells.2015.0118. [Epub ahead of print].
Atypical IgM multiple myeloma with deletion of c-MAF.
Juárez Salcedo LM et al. Int J Lab Hematol. 2015 May 20. doi: 10.1111/ijlh.12385. [Epub ahead of print].
A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.
Alagpulinsa DA et al. Cancer Biol Ther. 2015 May 21:0. [Epub ahead of print].
Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells.
Zhang W et al. Int J Nanomedicine. 2015 Apr 30;10:3275-89. doi: 10.2147/IJN.S80795. eCollection 2015.
Establishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis.
Martowicz A et al. J Vis Exp. 2015 May 1;(99). doi: 10.3791/52665.
Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.
Locke FL et al. J Immunother Cancer. 2015 May 19;3:20. doi: 10.1186/s40425-015-0065-1. eCollection 2015.
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
Morelli E et al. Leukemia. 2015 May 19. doi: 10.1038/leu.2015.124. [Epub ahead of print].
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.
Schott S et al. Invest New Drugs. 2015 May 20. [Epub ahead of print].
Cinobufagin exerts anti-proliferative and pro-apoptotic effects through the modulation ROS-mediated MAPKs signaling pathway.
Baek SH et al. Immunopharmacol Immunotoxicol. 2015 May 18:1-9. [Epub ahead of print].
Lenalidomide Enhances Immune Checkpoint Blockade Induced Immune Response in Multiple Myeloma.
Gorgun G et al. Clin Cancer Res. 2015 May 15. pii: clincanres.0200.2015. [Epub ahead of print].
The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.
Yang Y et al. J Biol Chem. 2015 May 15. pii: jbc.M115.663963. [Epub ahead of print].
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Hideshima T et al. Blood Cancer J. 2015 May 15;5:e312. doi: 10.1038/bcj.2015.38.
Genomic heterogeneity in multiple myeloma.
Szalat R et al. Curr Opin Genet Dev. 2015 May 13;30:56-65. doi: 10.1016/j.gde.2015.03.008. [Epub ahead of print].
A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.
Sharma R et al. Oncotarget. 2015 May 12. [Epub ahead of print].
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
Swaminathan B et al. Nat Commun. 2015 May 26;6:7213. doi: 10.1038/ncomms8213.
The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.
Zhu D et al. Nat Med. 2015 May 25. doi: 10.1038/nm.3867. [Epub ahead of print].
Proteasome inhibitors block Ikaros degradation by Lenalidomide in Multiple Myeloma.
Shi CX et al. Haematologica. 2015 May 14. pii: haematol.2015.124297. [Epub ahead of print].
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS et al. Leukemia. 2015 May 15. doi: 10.1038/leu.2015.123. [Epub ahead of print].
Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
Zhao Y et al. PLoS One. 2015 May 14;10(5):e0127334. doi: 10.1371/journal.pone.0127334. eCollection 2015.
Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche.
Zhang W et al. PLoS One. 2015 May 14;10(5):e0125995. doi: 10.1371/journal.pone.0125995. eCollection 2015.
Functional Analysis of microRNA in Multiple Myeloma.
Di Martino MT et al. Methods Mol Biol. 2015 May 14. [Epub ahead of print].
Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation.
Binsfeld M et al. Cancer Immunol Immunother. 2015 May 14. [Epub ahead of print].
miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor.
Shen X et al. Clin Exp Med. 2015 May 14. [Epub ahead of print].
Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments.
Wada A et al. Oncol Rep. 2015 Jun;33(6):2935-9. doi: 10.3892/or.2015.3941. Epub 2015 Apr 28.
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.
Mazzocco M et al. Immunology. 2015 May 9. doi: 10.1111/imm.12477. [Epub ahead of print].
Favourable prognostic impact of RAS mutation status in multiple myeloma treated with High-Dose Melphalan and Autologous Stem Cell Support in the era of novel agents – a single centre perspective.
Gebauer N et al. Leuk Lymphoma. 2015 May 7:1-9. [Epub ahead of print].
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
Sawyer JR et al. Blood. 2015 May 5. pii: blood-2015-03-632075. [Epub ahead of print].
Tumoricidal Effects of Macrophage-activating Immunotherapy in a Murine Model of Relapsed/ Refractory Multiple Myeloma.
Jensen JL et al. Cancer Immunol Res. 2015 May 4. pii: canimm.0025.2015. [Epub ahead of print].
The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA.
Segalla S et al. Nucleic Acids Res. 2015 Apr 29. pii: gkv387. [Epub ahead of print].
Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
Sarkar S et al. Cancer Immunol Immunother. 2015 Apr 29. [Epub ahead of print].
A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.
Trader DJ et al. J Am Chem Soc. 2015 May 20;137(19):6312-9. doi: 10.1021/jacs.5b02069. Epub 2015 May 8.
Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.
De Veirman K et al. Oncotarget. 2015 Apr 30;6(12):10532-47.
Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3.
Zhu S et al. Oncotarget. 2015 Apr 30;6(12):10460-72.
Modulation of cereblon levels by anti-myeloma agents.
Díaz-Rodríguez E et al. Leuk Lymphoma. 2015 May 12:1-10. [Epub ahead of print].